Veltuzumab Explained

Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma.^{[1] [2]}, it is undergoing Phase I/II clinical trials. When used with milatuzumab it showed activity.^[3]

This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106.^[4]

In August 2015 the US FDA granted it orphan drug status for immune thrombocytopenia (ITP).^[5] A phase II trial is planned to run for 5 years.^[5]

See also

• CD20 antagonist

Notes and References

1. http://www.ama-assn.org/ama1/pub/upload/mm/365/veltuzumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab
2. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH . CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas . Blood . 114 . 18 . 3864–71 . October 2009 . 19710501 . 2773491 . 10.1182/blood-2009-06-228890 .
3. Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA . 6 . The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma . British Journal of Haematology . 169 . 5 . 701–10 . June 2015 . 25847298 . 10.1111/bjh.13354 . 7297055 .
4. Book: Zibelman M, Borghaei H, Olszanski AJ . Dubel S, Reichert JM . Harnessing Innate Immunity . Handbook of Therapeutic Antibodies . https://books.google.com/books?id=I9k8BAAAQBAJ&pg=PA791 . 791 . 2014 . John Wiley & Sons . 2nd . 978-3-527-68244-7 . 10.1002/9783527682423.ch27 .
5. Web site: FDA grants orphan drug designation to veltuzumab for ITP . August 4, 2015 . HemOnc Today . Healio.com .